Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
4.820
-0.010 (-0.21%)
Sep 28, 2026, 1:37 PM EDT - Market open
Cingulate Employees
Cingulate had 14 employees as of December 31, 2025. The number of employees increased by 1 or 7.69% compared to the previous year.
Employees
14
Change (1Y)
1
Growth (1Y)
7.69%
Revenue / Employee
n/a
Profits / Employee
-$2,057,789
Market Cap
70.09M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 1 | 7.69% |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -2 | -13.33% |
| Dec 31, 2022 | 15 | -1 | -6.25% |
| Dec 31, 2021 | 16 | 4 | 33.33% |
| Sep 30, 2021 | 13 | 1 | 8.33% |
| Jun 30, 2021 | 13 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 214 |
| Gossamer Bio | 162 |
| XBiotech | 87 |
| Connect Biopharma Holdings | 64 |
| Pliant Therapeutics | 49 |
| Spero Therapeutics | 25 |
| MAIA Biotechnology | 13 |
| Aldeyra Therapeutics | 6 |
CING News
- 11 days ago - Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma - GlobeNewsWire
- 5 weeks ago - Cingulate price target lowered to $9 from $10 at Roth Capital - TheFly
- 6 weeks ago - Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness - GlobeNewsWire
- 6 weeks ago - Cingulate Earnings release: Q2 2026 - Filings
- 6 weeks ago - Cingulate Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Cingulate publishes peer-reviewed data on CTx-1301 pharmacokinetic profile - TheFly
- 6 weeks ago - Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile - GlobeNewsWire
- 2 months ago - Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology - GlobeNewsWire